What's new in NAFLD pathogenesis, biomarkers and treatment?

被引：44
作者：
Byrne, Christopher D. [1 ,2 ]
Targher, Giovanni [3 ]
机构：
[1] Univ Hosp Southampton, Southampton Gen Hosp, Southampton Natl Inst Hlth Res BioMed Res Centre, Southampton, England
[2] Univ Southampton, Fac Med, Nutr, Metab, Southampton, England
[3] Univ Verona, Dept Med,Sect Endocrinol,Diabet,Metab, Verona, Italy
来源：
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY | 2020年 / 17卷 / 02期
关键词：
HEPATOCELLULAR-CARCINOMA;
D O I：
10.1038/s41575-019-0239-2
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Advances have been made in the field of nonalcoholic fatty liver disease in 2019. One paper highlights the role of gut microbiota in hepatocellular carcinoma (HCC) pathogenesis, another presents a noninvasive algorithm for detecting advanced liver fibrosis and another suggests a potential novel approach to treating nonalcoholic steatohepatitis and suppressing HCC development. Key advances The altered gut microbiota profile is associated with systemic inflammation in patients with nonalcoholic fatty liver disease (NAFLD)-related cirrhosis who have hepatocellular carcinoma2 Measuring blood markers related to type III collagen might be useful for staging liver fibrosis in both adults and children with NAFLD5,6 Platelet count, activation and aggregation are increased in nonalcoholic steatohepatitis (NASH) and antiplatelet therapies should be tested10
引用
收藏
页码：70 / 71
页数：2
相关论文
共 10 条
  • [1] RATIONAL TESTING Tests for diagnosing and monitoring non-alcoholic fatty liver disease in adults
    Byrne, Christopher D.
    Patel, Janisha
    Scorletti, Eleonora
    Targher, Giovanni
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 2018, 362
  • [2] ADAPT: An Algorithm Incorporating PRO-C3 Accurately Identifies Patients With NAFLD and Advanced Fibrosis
    Daniels, Samuel J.
    Leeming, Diana J.
    Eslam, Mohammed
    Hashem, Ahmed M.
    Nielsen, Mette J.
    Krag, Aleksander
    Karsdal, Morten A.
    Grove, Jane I.
    Guha, Indra Neil
    Kawaguchi, Takumi
    Torimura, Takuji
    McLeod, Duncan
    Akiba, Jun
    Kaye, Philip
    de Boer, Bastiaan
    Aithal, Guruprasad P.
    Adams, Leon A.
    George, Jacob
    [J]. HEPATOLOGY, 2019, 69 (03) : 1075 - 1086
  • [3] Promotion of Hepatocellular Carcinoma by the Intestinal Microbiota and TLR4
    Dapito, Dianne H.
    Mencin, Ali
    Gwak, Geum-Youn
    Pradere, Jean-Philippe
    Jang, Myoung-Kuk
    Mederacke, Ingmar
    Caviglia, Jorge M.
    Khiabanian, Hossein
    Adeyemi, Adebowale
    Bataller, Ramon
    Lefkowitch, Jay H.
    Bower, Maureen
    Friedman, Richard
    Sartor, R. Balfour
    Rabadan, Raul
    Schwabe, Robert F.
    [J]. CANCER CELL, 2012, 21 (04) : 504 - 516
  • [4] Platelets mediate cytotoxic T lymphocyte-induced liver damage
    Iannacone, M
    Sitia, G
    Isogawa, M
    Marchese, P
    Castro, MG
    Lowenstein, PR
    Chisari, FV
    Ruggeri, ZM
    Guidotti, LG
    [J]. NATURE MEDICINE, 2005, 11 (11) : 1167 - 1169
  • [5] Platelet GPIbα is a mediator and potential interventional target for NASH and subsequent liver cancer
    Malehmir, Mohsen
    Pfister, Dominik
    Gallage, Suchira
    Szydlowska, Marta
    Inverso, Donato
    Kotsiliti, Elena
    Leone, Valentina
    Peiseler, Moritz
    Surewaard, Bas G. J.
    Rath, Dominik
    Ali, Adnan
    Wolf, Monika Julia
    Drescher, Hannah
    Healy, Marc E.
    Dauch, Daniel
    Kroy, Daniela
    Krenkel, Oliver
    Kohlhepp, Marlene
    Engleitner, Thomas
    Olkus, Alexander
    Sijmonsma, Tjeerd
    Volz, Julia
    Deppermann, Carsten
    Stegner, David
    Helbling, Patrick
    Nombela-Arrieta, Cesar
    Rafiei, Anahita
    Hinterleitner, Martina
    Rall, Marcel
    Baku, Florian
    Borst, Oliver
    Wilson, Caroline L.
    Leslie, Jack
    O'Connor, Tracy
    Weston, Christopher J.
    Adams, David H.
    Sheriff, Lozan
    Teijeiro, Ana
    Prinz, Marco
    Bogeska, Ruzhica
    Anstee, Natasha
    Bongers, Malte N.
    Notohamiprodjo, Mike
    Geisler, Tobias
    Withers, Dominic J.
    Ware, Jerry
    Mann, Derek A.
    Augustin, Hellmut G.
    Vegiopoulos, Alexandros
    Milsom, Michael D.
    [J]. NATURE MEDICINE, 2019, 25 (04) : 641 - +
  • [6] Plasma N-terminal propeptide of type III procollagen accurately predicts liver fibrosis severity in children with non-alcoholic fatty liver disease
    Mosca, Antonella
    Comparcola, Donatella
    Romito, Ilaria
    Mantovani, Alessandro
    Nobili, Valerio
    Byrne, Christopher D.
    Alisi, Anna
    Targher, Giovanni
    [J]. LIVER INTERNATIONAL, 2019, 39 (12) : 2317 - 2329
  • [7] Platelets as Key Factors in Hepatocellular Carcinoma
    Pavlovic, Natasa
    Rani, Bhavna
    Gerwins, Par
    Heindryckx, Femke
    [J]. CANCERS, 2019, 11 (07)
  • [8] Hepatocellular Carcinoma Is Associated With Gut Microbiota Profile and Inflammation in Nonalcoholic Fatty Liver Disease
    Ponziani, Francesca Romana
    Bhoori, Sherrie
    Castelli, Chiara
    Putignani, Lorenza
    Rivoltini, Licia
    Del Chierico, Federica
    Sanguinetti, Maurizio
    Morelli, Daniele
    Sterbini, Francesco Paroni
    Petito, Valentina
    Reddel, Sofia
    Calvani, Riccardo
    Camisaschi, Chiara
    Picca, Anna
    Tuccitto, Alessandra
    Gasbarrini, Antonio
    Pompili, Maurizio
    Mazzaferro, Vincenzo
    [J]. HEPATOLOGY, 2019, 69 (01) : 107 - 120
  • [9] Past, present and future perspectives in nonalcoholic fatty liver disease
    Sanyal, Arun J.
    [J]. NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY, 2019, 16 (06) : 377 - 386
  • [10] Antiplatelet therapy prevents hepatocellular carcinoma and improves survival in a mouse model of chronic hepatitis B
    Sitia, Giovanni
    Aiolfi, Roberto
    Di Lucia, Pietro
    Mainetti, Marta
    Fiocchi, Amleto
    Mingozzi, Francesca
    Esposito, Antonio
    Ruggeri, Zaverio M.
    Chisari, Francis V.
    Iannacone, Matteo
    Guidotti, Luca G.
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2012, 109 (32) : E2165 - E2172
1